Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer

著者: Peng, Jingyuan, Tan, Chongqing, Zeng, Xiaohui, Liu, Shikun
出版年 PLoS One (2018)

Cost-effectiveness analysis of positron-emission tomography-computed tomography in preoperative staging for nonsmall-cell lung cancer with resected monometastatic disease

著者: Zeng, Xiaohui, Peng, Liubao, Tan, Chongqing, Wang, Yunhua
出版年 Medicine (Baltimore) (2019)

First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis

著者: Liu, Qiao, Luo, Xia, Yi, Lidan, Zeng, Xiaohui, Tan, Chongqing
出版年 Front Oncol (2021)

A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Canc...

著者: Wang, Siying, Peng, Liubao, Li, Jianhe, Zeng, Xiaohui, Ouyang, Lihui, Tan, Chongqing, Lu, Qiong
出版事項 2013

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA

著者: Zeng, Xiaohui, Wan, Xiaomin, Peng, Liubao, Peng, Ye, Ma, Fang, Liu, Qiao, Tan, Chongqing
出版年 BMJ Open (2019)

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

著者: Liu, Qiao, Luo, Xia, Peng, Liubao, Yi, Lidan, Wan, Xiaomin, Zeng, Xiaohui, Tan, Chongqing
出版年 Clin Drug Investig (2019)

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China

著者: Liu, Qiao, Luo, Xia, Peng, Liubao, Yi, Lidan, Wan, Xiaomin, Zeng, Xiaohui, Tan, Chongqing
出版年 BMJ Open (2020)

First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis

著者: Wan, XiaoMin, Zhang, YuCong, Tan, ChongQing, Zeng, XiaoHui, Peng, LiuBao
出版年 JAMA Oncol (2019)

Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China

著者: Li, Sini, Peng, Liubao, Tan, Chongqing, Zeng, Xiaohui, Wan, Xiaomin, Luo, Xia, Yi, Lidan, Li, Jianhe
出版年 PLoS One (2020)

Economic Evaluation of First-Line Adjuvant Chemotherapies for Resectable Gastric Cancer Patients in China

著者: Tan, Chongqing, Peng, Liubao, Zeng, Xiaohui, Li, Jianhe, Wan, Xiaomin, Chen, Gannong, Yi, Lidan, Luo, Xia, Zhao, Ziying
出版事項 2013

Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model Analysis

著者: Zeng, Xiaohui, Li, Jianhe, Peng, Liubao, Wang, Yunhua, Tan, Chongqing, Chen, Gannong, Wan, Xiaomin, Lu, Qiong, Yi, Lidan
出版事項 2014

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer

著者: Han, Jiaqi, Xiao, Desheng, Tan, Chongqing, Zeng, Xiaohui, Hu, Huabin, Zeng, Shan, Jiang, Qin, She, Longjiang, Yao, Linli, Li, Li, Tang, Lanhua, Ma, Jian, Huang, Jin, Shen, Liangfang
出版年 Cancer Control (2020)